Asperolide A, a marine-derived agent, attenuates breast cancer-induced osteolysis through the inhibition of osteoclast differentiation and bone resorption by blocking the PI3K/AKT/mTOR/c-FOS/NFATc1 axis. This evidence concerns the gene MTOR and breast cancer.